CVS Health Corporation (CVS) Key Metrics
CVS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $118.13B
- Enterprise value
- $172.16B
- P/E (TTM)
- 24.3 10-yr median 14.6
- Forward P/E
- 10.7
- PEG ratio
- 0.21
- Price / sales
- 0.3 10-yr median 0.4
- Price / book
- 1.4 10-yr median 1.4
- EV / EBITDA
- 13.3 10-yr median 11.1
- Dividend yield
- 2.88% $2.66 a year
- Beta
- 0.60
CVS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCVS valuation Price multiples at each fiscal year-end price.
CVS returns How much profit the business earns on the capital it uses.
CVS per-share figures Results divided by the shares outstanding at year-end.
CVS financial health Debt, liquidity and how easily interest is covered.
CVS efficiency & capital use Working capital cycle and where the cash goes.
CVS valuation history
CVS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CVS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CVS cash returned to shareholders
CVS price vs earnings per share
CVS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $100.87B | $56.65B | $101.86B | $123.29B | $137.10B | $89.75B | $96.95B | $68.40B | $74.24B | $85.14B |
| Enterprise value | $183.80B | $128.58B | $169.79B | $178.30B | $200.57B | $163.93B | $177.89B | $135.25B | $99.44B | $109.22B |
| P/E ratio | 57.1 | 12.3 | 12.2 | 28.6 | 17.1 | 12.5 | 14.6 | — | 11.2 | 16.0 |
| Price / sales | 0.3 | 0.2 | 0.3 | 0.4 | 0.5 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 |
| Price / book | 1.3 | 0.7 | 1.3 | 1.7 | 1.8 | 1.3 | 1.5 | 1.2 | 2.0 | 2.3 |
| Price / free cash flow | 12.9 | 9.0 | 9.8 | 9.2 | 8.7 | 6.7 | 9.3 | 10.0 | 12.2 | 10.8 |
| Price / operating cash flow | 9.5 | 6.2 | 7.6 | 7.6 | 7.5 | 5.7 | 7.5 | 7.7 | 9.3 | 8.4 |
| EV / sales | 0.5 | 0.3 | 0.5 | 0.6 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.6 |
| EV / EBITDA | 18.6 | 9.4 | 12.4 | 14.4 | 11.4 | 9.6 | 10.8 | 20.1 | 8.4 | 9.0 |
| EV / free cash flow | 23.5 | 20.3 | 16.3 | 13.3 | 12.7 | 12.2 | 17.1 | 19.8 | 16.3 | 13.8 |
| Earnings yield | 1.8% | 8.1% | 8.2% | 3.5% | 5.8% | 8.0% | 6.8% | −0.9% | 8.9% | 6.2% |
| Free cash flow yield | 7.7% | 11.2% | 10.2% | 10.9% | 11.5% | 15.0% | 10.7% | 10.0% | 8.2% | 9.3% |
| Dividend yield | 3.4% | 6.0% | 3.1% | 2.4% | 1.9% | 2.9% | 2.7% | 3.0% | 2.8% | 2.2% |
| Shareholder yield (dividends + buybacks) | 3.4% | 11.3% | 5.1% | 5.2% | 1.9% | 2.9% | 2.7% | 3.1% | 8.6% | 7.4% |
| Share price at fiscal year-end | $79.36 | $44.89 | $78.96 | $93.19 | $103.16 | $68.30 | $74.29 | $65.52 | $72.50 | $78.91 |
| Per share | ||||||||||
| Revenue per share | $316.34 | $295.41 | $277.35 | $243.74 | $219.80 | $204.49 | $196.76 | $186.38 | $180.46 | $164.55 |
| Earnings per share | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 | $5.46 | $5.08 | −$0.57 | $6.47 | $4.93 |
| Operating cash flow per share | $8.37 | $7.22 | $10.41 | $12.23 | $13.74 | $12.07 | $9.85 | $8.49 | $7.82 | $9.40 |
| Free cash flow per share | $6.14 | $5.01 | $8.06 | $10.17 | $11.85 | $10.22 | $7.96 | $6.54 | $5.95 | $7.34 |
| Cash per share | $8.38 | $8.71 | $8.88 | $11.88 | $9.42 | $8.26 | $6.17 | $6.30 | $1.76 | $3.20 |
| Book value per share | $59.18 | $59.87 | $59.27 | $54.02 | $56.49 | $52.81 | $48.94 | $55.77 | $36.81 | $34.13 |
| Tangible book value per share | −$28.14 | −$34.10 | −$34.14 | −$23.80 | −$24.88 | −$31.43 | −$37.55 | −$54.58 | −$14.05 | −$13.84 |
| Dividends per share | $2.67 | $2.67 | $2.43 | $2.20 | $1.98 | $2.00 | $1.99 | $1.95 | $2.00 | $1.71 |
| Capex per share | $2.23 | $2.20 | $2.35 | $2.06 | $1.90 | $1.85 | $1.88 | $1.95 | $1.87 | $2.06 |
| Debt per share | $73.64 | $65.71 | $61.54 | $53.46 | $57.19 | $64.72 | $68.20 | $70.33 | $26.37 | $25.52 |
| Shares outstanding | 1.27B | 1.26B | 1.29B | 1.32B | 1.33B | 1.31B | 1.30B | 1.04B | 1.02B | 1.08B |
| Change in shares outstanding | +0.7% | −2.2% | −2.5% | −0.5% | +1.1% | +0.7% | +25.0% | +2.0% | −5.1% | −4.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 2.3% | 6.1% | 11.3% | 5.9% | 11.1% | 10.8% | 10.9% | −1.2% | 17.8% | 14.4% |
| Return on invested capital (ROIC) | 5.5% | 4.4% | 7.6% | 4.5% | 7.2% | 7.1% | 6.5% | 2.1% | 12.4% | 10.4% |
| Return on assets (ROA) | 0.7% | 1.8% | 3.5% | 1.9% | 3.5% | 3.2% | 3.2% | −0.4% | 7.0% | 5.7% |
| Return on tangible assets | 1.2% | 3.4% | 6.5% | 3.4% | 6.4% | 6.0% | 6.1% | −0.7% | 15.4% | 12.5% |
| Free cash flow margin | 1.9% | 1.7% | 2.9% | 4.2% | 5.4% | 5.0% | 4.0% | 3.5% | 3.3% | 4.5% |
| Income quality (OCF / net income) | 6.02 | 1.97 | 1.61 | 3.75 | 2.28 | 2.21 | 1.94 | — | 1.21 | 1.91 |
| Financial health | ||||||||||
| Total debt | $93.59B | $82.92B | $79.39B | $70.73B | $76.00B | $85.04B | $89.00B | $73.43B | $27.00B | $27.53B |
| Cash & short-term investments | $10.66B | $10.99B | $11.46B | $15.72B | $12.53B | $10.85B | $8.06B | $6.58B | $1.81B | $3.46B |
| Net debt | $82.94B | $71.93B | $67.93B | $55.01B | $63.47B | $74.19B | $80.95B | $66.85B | $25.20B | $24.07B |
| Debt / equity | 1.24 | 1.10 | 1.04 | 0.99 | 1.01 | 1.23 | 1.39 | 1.26 | 0.72 | 0.75 |
| Debt / assets | 0.36 | 0.33 | 0.32 | 0.31 | 0.33 | 0.37 | 0.40 | 0.37 | 0.28 | 0.29 |
| Net debt / EBITDA | 8.41 | 5.26 | 4.94 | 4.46 | 3.62 | 4.33 | 4.93 | 9.91 | 2.13 | 1.97 |
| Current ratio | 0.84 | 0.81 | 0.86 | 0.95 | 0.88 | 0.91 | 0.94 | 1.03 | 1.02 | 1.18 |
| Quick ratio | 0.63 | 0.60 | 0.63 | 0.67 | 0.62 | 0.61 | 0.62 | 0.65 | 0.52 | 0.62 |
| Interest coverage | 3.3 | 2.9 | 5.2 | 3.5 | 5.3 | 4.8 | 3.9 | 1.5 | 9.0 | 9.6 |
| Working capital | −$13.98B | −$15.96B | −$11.33B | −$3.79B | −$7.80B | −$5.65B | −$3.00B | $1.23B | $581.0M | $4.79B |
| Invested capital | $158.15B | $147.49B | $144.39B | $126.48B | $138.55B | $143.58B | $144.81B | $125.07B | $62.89B | $60.90B |
| Tangible asset value | −$35.60B | −$42.87B | −$43.87B | −$31.18B | −$32.77B | −$40.99B | −$48.70B | −$56.66B | −$14.39B | −$14.93B |
| Net current asset value | −$110.97B | −$108.84B | −$105.23B | −$90.87B | −$97.61B | −$104.64B | −$107.98B | −$92.67B | −$26.21B | −$26.59B |
| Graham number | $43.04 | $70.18 | $92.88 | $62.93 | $87.48 | $80.57 | $74.82 | — | $73.18 | $61.52 |
| Graham net-net per share | −$106.66 | −$103.08 | −$97.83 | −$83.73 | −$88.71 | −$94.83 | −$97.13 | −$105.25 | −$37.20 | −$34.91 |
| Capital allocation | ||||||||||
| Dividends paid | $3.40B | $3.37B | $3.13B | $2.91B | $2.62B | $2.62B | $2.60B | $2.04B | $2.05B | $1.84B |
| Share buybacks (net) | $0 | $3.02B | $2.01B | $3.50B | $0 | $0 | $0 | $97.0M | $4.36B | $4.46B |
| Dividend payout ratio | 192.1% | 73.1% | 37.5% | 67.4% | 32.8% | 36.6% | 39.2% | — | 30.9% | 34.6% |
| Dividends + buybacks / free cash flow | 43.5% | 101.1% | 49.5% | 47.6% | 16.7% | 19.5% | 25.1% | 31.3% | 105.3% | 79.6% |
| Capex / revenue | 0.7% | 0.7% | 0.8% | 0.8% | 0.9% | 0.9% | 1.0% | 1.0% | 1.0% | 1.3% |
| Capex / operating cash flow | 26.6% | 30.5% | 22.6% | 16.9% | 13.8% | 15.4% | 19.1% | 23.0% | 24.0% | 21.9% |
| Capex / depreciation | 0.61 | 0.60 | 0.69 | 0.64 | 0.56 | 0.55 | 0.56 | 0.75 | 0.77 | 0.90 |
| Stock-based compensation / revenue | 0.1% | 0.1% | 0.2% | 0.1% | 0.2% | 0.1% | 0.2% | 0.1% | 0.1% | 0.1% |
| SG&A / revenue | 0.2% | 11.1% | 11.0% | 11.8% | 12.6% | 13.1% | 12.7% | 10.7% | 10.0% | 10.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 34.6 | 35.1 | 31.9 | 29.3 | 28.8 | 28.1 | 26.5 | 28.9 | 25.0 | 24.7 |
| Days of inventory on hand | 19.7 | 20.5 | 22.3 | 25.1 | 27.6 | 29.9 | 29.3 | 35.5 | 35.1 | 35.3 |
| Days payables outstanding | 39.6 | 17.5 | 17.9 | 18.6 | 18.0 | 18.0 | 16.8 | 19.9 | 19.6 | 18.9 |
| Cash conversion cycle (days) | 14.6 | 38.1 | 36.3 | 35.7 | 38.4 | 40.0 | 39.0 | 44.5 | 40.5 | 41.1 |
| Receivables turnover | 10.55 | 10.40 | 11.45 | 12.47 | 12.65 | 12.99 | 13.79 | 12.63 | 14.58 | 14.76 |
| Payables turnover | 9.21 | 20.88 | 20.40 | 19.57 | 20.27 | 20.31 | 21.76 | 18.33 | 18.59 | 19.27 |
| Inventory turnover | 18.56 | 17.79 | 16.35 | 14.54 | 13.24 | 12.20 | 12.44 | 10.27 | 10.40 | 10.34 |
| Asset turnover | 1.56 | 1.48 | 1.50 | 1.40 | 1.26 | 1.19 | 1.23 | 1.33 | 1.95 | 1.90 |
| Average receivables | $38.12B | $35.85B | $31.25B | $25.85B | $23.09B | $20.68B | $18.62B | $15.41B | $12.67B | $12.03B |
| Average payables | $37.64B | $15.39B | $14.87B | $13.69B | $11.84B | $10.81B | $9.71B | $8.89B | $8.40B | $7.72B |
| Average inventory | $18.68B | $18.07B | $18.56B | $18.43B | $18.13B | $18.01B | $16.98B | $15.87B | $15.03B | $14.38B |
| Intangibles / total assets | 42.5% | 46.8% | 48.3% | 45.1% | 46.4% | 48.0% | 50.7% | 58.6% | 54.7% | 54.8% |
Computed from CVS's annual financial statements (latest annual report filed February 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CVS valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), CVS Health traded at 57.1 times earnings, against a 10-year median of 14.6. Based on the latest twelve months, the trailing P/E is 24.3 and the forward P/E is 10.7. CVS Health earned a return on equity of 2.3% and a return on invested capital of 5.5% in fiscal 2025. It ended the year with $93.6 billion of debt and $10.7 billion in cash and short-term investments, net debt of $82.9 billion. It returned $3.4 billion to shareholders: $3.4 billion in dividends and $0 in share buybacks, 44% of free cash flow. The share count rose 17.8% from 1.08B to 1.27B over 9 years.
See the CVS income statement, the CVS chart for price history, or the CVS stock overview for the latest quote and news.
CVS key metrics FAQ
What is CVS Health's P/E ratio?
CVS Health's trailing P/E ratio is 24.3 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 10.7. At the end of fiscal 2025 it was 57.1, compared with a 10-year median of 14.6.
What is CVS Health's EV/EBITDA?
CVS Health's enterprise value was 18.6 times EBITDA at the end of fiscal 2025 (enterprise value $183.8 billion, EBITDA $9.9 billion); the current EV/EBITDA is 13.3.
What is CVS Health's return on equity?
CVS Health's return on equity (ROE) was 2.3% in fiscal 2025: net income of $1.8 billion on average shareholders' equity of $75.4 billion.
What is CVS Health's ROIC?
CVS Health's return on invested capital was 5.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does CVS Health have?
CVS Health had total debt of $93.6 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.24 and $82.9 billion of net debt (8.41 times EBITDA).
What is CVS Health's dividend yield?
CVS Health's forward dividend yield is 2.88%. CVS Health paid $3.4 billion in dividends in fiscal 2025 ($2.67 per share), a payout ratio of 192.1%.
What is CVS Health's free cash flow yield?
CVS Health generated $7.8 billion of free cash flow in fiscal 2025, a free cash flow yield of 7.7% on its market value at year-end ($100.9 billion).
What is CVS Health's current ratio?
CVS Health's current ratio was 0.84 at the end of fiscal 2025: current assets were 0.84 times current liabilities.